I am not sure what drug Bianstrene is, but the drug RAC is developing is called bisantrene and was originally developed in the 1970s. Bisantrene went all the way through to marketing approval for AML in France in 1988. It was dropped after approval by the original big pharma developer (Lederle Laboratories, now part of Pfizer) due to formulation issues in favour of another anticancer drug they had developed called mitoxantrone. These sort of outcomes are quite common in the pharma industry where good drugs are dropped for reasons other than clinical efficacy.
RAC has solved the formulation issues and identified the indications and markets that offer the most potential for bisantrene. This has all been outlined in detail in our recent investor update which you may find helpful to read.
https://hotcopper.com.au/threads/ann-rac-investor-presentation-may-2024.7998573
Cardioprotection thread, page-529
- There are more pages in this discussion • 44 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.75 |
Change
0.180(11.5%) |
Mkt cap ! $296.8M | |||
| Open | High | Low | Value | Volume |
| $1.58 | $1.80 | $1.58 | $772.4K | 450.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2354 | $1.75 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.76 | 525 | 1 |
View Market Depth
| Last trade - 16.10pm 06/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.75 |
Change
0.180 ( 11.2 %) |
||||
| Open | High | Low | Volume | ||
| $1.60 | $1.80 | $1.58 | 22024 | ||
| Last updated 15.59pm 06/06/2024 ? | |||||
| RAC (ASX) Chart |